Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
The Food and Drug Administration (FDA) has issued a de novo clearance for Stone Clear, an ultrasound device that enables post-lithotripsy passage of kidney stone fragments.1
Through ultrasound propulsion, the Stone Clear modality reportedly repositions residual kidney stone fragments from lithotripsy procedures, allowing easier natural passage and clearance, according to SonoMotion, the manufacturer of Stone Clear.1 The company said the Stone Clear procedure does not require anesthesia and can be completed in 15 minutes.
A recent prospective multicenter trial found that ultrasound propulsion with the Stone Clear device facilitated a 70 percent lower risk of relapse in comparison to observation in a control group.2
"Patients with post-lithotripsy residual fragments are more likely to have complications, emergency department visits, or repeat procedures, yet they have no reliable non-invasive option aside from passive observation," said James E. Lingeman, M.D., a clinical professor of urology at the Indiana University School of Medicine. "The Stone Clear device provides patients with a non-invasive option to reduce their residual fragment stone burden in the clinic environment while being fully awake."
References
1. SonoMotion. SonoMotion announces FDA de novo clearance for its Stone Clear device. PR Newswire. Available at: https://www.prnewswire.com/news-releases/sonomotion-announces-fda-de-novo-clearance-for-its-stone-clear-device-302303764.html . Published November 13. 2024. Accessed November 13, 2024.
2. Sorenson MD, Dunmire B, Thiel J, et al. Randomized controlled trial of ultrasonic propulsion-facilitated clearance of residual kidney stone fragments vs observation. J Urol. 2024;212(6):811-820.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Intestinal Ultrasound Provide an Alternative for Evaluating Creeping Fat with Crohn’s Disease?
September 25th 2024Intestinal ultrasound demonstrated an 88.2 percent agreement with computed tomography enterography in characterizing creeping fat in patients with Crohn’s disease, according to new research.
FDA Clears Enhanced 3D Ultrasound Platform for Thyroid Imaging
September 23rd 2024The Piur tUS Infinity system reportedly reduces operator dependency with ultrasound through upgrading of two-dimensional ultrasound devices and access to 3D multiplanar image reconstructions of thyroid conditions.